Jun 7, 2017

New medical device monitors heart data at home

Eko Devices

The Food and Drug Administration has cleared Eko Devices to sell a new product called DUO — a device that digitally combines a stethoscope and electrocardiogram.

How DUO works: Patients hold the handheld device near their heart, and doctors can monitor the heart sounds and images from afar in real time. Doctors can buy a DUO for $350 and distribute them to patients free of charge as part of an outpatient program, said Jason Bellet, co-founder of Eko Devices. Patients can also get the device through a doctor's prescription.

Why it matters: Skepticism is warranted for new health tech gadgets. But it could fill a need since doctors want to prevent hospital readmissions (partially due to government incentives). This kind of remote technology "enables us to know which patients are ill and need immediate attention versus those who are stable and can continue therapy at home," said Dr. Ami Bhatt, director of outpatient cardiology at Massachusetts General Hospital in Boston.

Go deeper

SoftBank to cut its stake to get T-Mobile's Sprint deal done

Illustration: Rebecca Zisser/Axios

T-Mobile and Sprint announced a revised merger agreement that will see SoftBank getting a smaller share of the combined company, while most shareholders will receive the previously agreed upon exchange rate. The companies said they hope to get the deal as early as April 1.

Why it matters: The amended deal reflects the decline in Sprint's business, while leaving most shareholders' stake intact and removing another hurdle to the deal's closure.

Trump indulges Wall Street with Milken pardon

Photo Illustration: Sarah Grillo/Axios. Photo: Chris Graythen/Getty Images

Donald Trump loves Wall Street shenanigans. Companies owned by him have declared bankruptcy six different times, and he was once sued alongside Mike Milken for participating in a scheme to artificially inflate junk-bond prices.

Driving the news: Trump pardoned Milken this week, with an official statement positively gushing over Milken's role in developing the wilder side of fixed-income capital markets.